| Cub Pharmacy 1598/682 | |
| 12595 Central Ave Ne, Blaine, Minnesota 55434 | |
| (763) 767-4329 |
| Name | Cub Pharmacy 1598/682 |
|---|---|
| Organization Name | Supervalu Pharmacies Inc |
| Location | 12595 Central Ave Ne, Blaine, Minnesota 55434 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (763) 767-4329 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.
Microfluidic Systems (MFSI), a privately-held company, announced today that it has been awarded a series of patents covering both the components and integrated systems that perform fully automated sample collection through identification of air-borne pathogens such as bacteria, viruses, and toxins.
Bone morphogenetic proteins, commonly used off-label to enhance pediatric spinal fusion (spinal arthrodesis), did not improve revision rates for pediatric spinal fusion, according to a study presented on March 14 at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego.
A research team at the Institut Pasteur in France describes the successful development of such a vaccine utilizing a measles virus vector.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite potential safety concerns, Jazz Pharmaceuticals/UCB's sodium oxybate (JZP-6) will account for more than 15 percent of the fibromyalgia drug market in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Sodium oxybate has demonstrated robust efficacy in Phase III clinical trials for fibromyalgia and interviewed thought leaders are impressed with its effect on several key symptom domains of fibromyalgia, which include pain, sleep and fatigue.
› Verified 9 days ago
| NPI Number | 1043326457 |
| Organization Name | SUPERVALU PHARMACIES INC |
| Doing Business As | CUB PHARMACY |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 12595 Central Ave Ne, Blaine, MN 55434 |
| Phone Number | 763-767-4329 |
News Archive
Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.
Microfluidic Systems (MFSI), a privately-held company, announced today that it has been awarded a series of patents covering both the components and integrated systems that perform fully automated sample collection through identification of air-borne pathogens such as bacteria, viruses, and toxins.
Bone morphogenetic proteins, commonly used off-label to enhance pediatric spinal fusion (spinal arthrodesis), did not improve revision rates for pediatric spinal fusion, according to a study presented on March 14 at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego.
A research team at the Institut Pasteur in France describes the successful development of such a vaccine utilizing a measles virus vector.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite potential safety concerns, Jazz Pharmaceuticals/UCB's sodium oxybate (JZP-6) will account for more than 15 percent of the fibromyalgia drug market in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Sodium oxybate has demonstrated robust efficacy in Phase III clinical trials for fibromyalgia and interviewed thought leaders are impressed with its effect on several key symptom domains of fibromyalgia, which include pain, sleep and fatigue.
› Verified 9 days ago
News Archive
Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.
Microfluidic Systems (MFSI), a privately-held company, announced today that it has been awarded a series of patents covering both the components and integrated systems that perform fully automated sample collection through identification of air-borne pathogens such as bacteria, viruses, and toxins.
Bone morphogenetic proteins, commonly used off-label to enhance pediatric spinal fusion (spinal arthrodesis), did not improve revision rates for pediatric spinal fusion, according to a study presented on March 14 at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego.
A research team at the Institut Pasteur in France describes the successful development of such a vaccine utilizing a measles virus vector.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite potential safety concerns, Jazz Pharmaceuticals/UCB's sodium oxybate (JZP-6) will account for more than 15 percent of the fibromyalgia drug market in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Sodium oxybate has demonstrated robust efficacy in Phase III clinical trials for fibromyalgia and interviewed thought leaders are impressed with its effect on several key symptom domains of fibromyalgia, which include pain, sleep and fatigue.
› Verified 9 days ago
Cvs Pharmacy #07152 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2357 108th Ln Ne, Blaine, Minnesota 55449 Phone: (763) 780-0776 | |
Cvs Pharmacy #16953 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1500 109th Ave Ne, Blaine, Minnesota 55449 Phone: (763) 354-1001 | |
Walgreens #5413 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 600 County Road 10 Ne, Blaine, Minnesota 55434 Phone: (763) 786-9081 | |
Walgreens #7781 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 4202 Pheasant Ridge Dr Ne, Blaine, Minnesota 55449 Phone: (651) 255-1498 | |
Walgreens #7218 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 12480 Aberdeen St Ne, Blaine, Minnesota 55449 Phone: (763) 862-6596 |